Fumaric acid esters: An alternative systemic treatment for psoriasis

Clinical and Experimental Dermatology

Volumn 24, Issue 5, 1999, Pages 361-364

  Ameen, M ^a   Russell Jones, R ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; DITHRANOL; ETRETINATE; FUMADERM; FUMARIC ACID DERIVATIVE; HYDROXYUREA; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TAR; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ADULT; ARTICLE; CASE REPORT; DIARRHEA; HUMAN; LEUKOCYTOCLASTIC VASCULITIS; MALE; NAUSEA; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; SKIN IRRITATION; UNITED KINGDOM;

FUMARATES; HUMANS; MALE; MIDDLE AGED; PSORIASIS;

EID: 0032834958     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.1999.00501.x     Document Type: Article

References (16)

1. Scheweckendiek W. Heilung von Psoriasis. Med Montatschr 1959: 103-4.
2. Schafer GN, Fumarsaure lindert die Schuppenflechte. Selecta 1984; 15: 1260-1
3. Nieboer C, de Hoop D, van Loenen AC et al. Systemic therapy with fumaric acid derivatives: New possibilities in the treatment of psoriasis. J Am Acad Dermatol 1989; 20 (4):601-8.
4. Nugteren-Huying WM, van der Schroeff JG et al. Fumaric acid therapy for psoriasis: a randomised, double-blind, placebo-controlled study. J Am Acad Dermatol 1990; 2(1): 311-2.
5. Nieboer C, de Hoop D, Langendijk PNJ et al. Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester. Dermatologica 1990; 181: 33-7.
6. Altmeyer PJ, Matthes U, Pawlak F et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 1994: 30:977-81.
7. Mrowietz U, Christophers E. Altmeyer P et al. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. Br J Dermatol 1998: 138: 456-60.
8. Thio HB, van der Schroeff JG. Nugteren-Huying WM et al. Long-term systemic therapy with dimethylfumarate and monoethylfumarate (Fumaderm) in psoriasis. J Eur Acad Dermatol Venereol 1995: 4: 35-40.
9. Kolbach DN, Nicboer C. Fumaric acid therapy in psoriasis: Results and side-effects of two years of treatment. J Am Acad Dermatol 1992; 27: 769-71.
10. Roodnat JL, Christiaans MH, Nugteren-Huying WM et al. Acute kidney insufficiency in the treatment of psoriasis using fumaric esters. Schweiz Med Wochenscher 1989: 119(23): 826-30.
11. Stuhlinger W, Innerebner M, Aberer W. The nephrotoxic effect of therapy with fumaric acid esters in psoriasis. Deutsch Med Wochenschr 1990; 115 (45): 1712-5.
12. Altmeyer P, Hartwig R. Matthes H. Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients. Hautarzt 1996: 47 (3): 190-6.
13. Ockenfels HM, Schultewolter T, Ockenfels G et al. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol 1998; 139: 390-5.
14. De Jong P, Bezemer AC, Van Zomerdijk TPL et al. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethyllumarate. Eur J Immunol 1996; 26: 2067-74.
15. Asadullah K, Schmid H. Friedrich M et al. Influence of monomethylfumarate on monocytic cytokine formation - explanation for adverse and therapeutic effects in psoriasis? Arch Dermatol Res 1997; 289: 623-30.
16. Vandermeeren M. Janssens S et al. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin. VCAM-1 and ICAM-1 expression in human endothelial cells. Biochem Biophys Res Commun 1997; 234: 19-23.